CYP19A1 and breast carcinoma: In recent years, the role of tamoxifen in postmenopausal breast cancer patients has been challenged by aromatase inhibitors (AIs) [7], [8], which have been considered to be an optimal adjuvant endocrine treatment for postmenopausal women with hormone receptor-positive breast cancer [9]–[11].